Keymed Biosciences Inc. (2162.HK)
HKD 33.0
(-1.93%)
HKD 33.0
(-1.93%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -303.62 Million | -401.93 Million | -214.63 Million | -119.36 Million | -68.37 Million |
| Net Income | -356.18 Million | -303.59 Million | -3.89 Billion | -818.84 Million | -167.51 Million |
| Depreciation & Amortization | 69.16 Million | 36.12 Million | 21.01 Million | 18.99 Million | 12.29 Million |
| Deferred income taxes | - | - | 56.14 Million | - | - |
| Stock-based compensation | 40.07 Million | 48.56 Million | 116.82 Million | - | - |
| Change in working capital | 22.42 Million | -5.67 Million | 2.82 Million | -187 Thousand | -6.94 Million |
| Other non-cash items | -71.51 Million | -177.35 Million | 3.48 Billion | 680.68 Million | 93.77 Million |
| Investing Cash Flow | 468.2 Million | -645.58 Million | -2.03 Billion | -113.06 Million | -58.02 Million |
| Investments in PPE | -382.61 Million | -279.54 Million | -172.85 Million | -19.89 Million | -62.3 Million |
| Acquisitions | - | - | -21 Million | 4.62 Million | 38 Thousand |
| Investment purchases | -905.23 Million | -5.65 Billion | -2.75 Billion | -676.96 Million | -257 Million |
| Sales/Maturities of investments | 1.6 Billion | 5.07 Billion | 904.11 Million | 572.08 Million | 260.16 Million |
| Other Investing Activities | 63.56 Million | 208.98 Million | 6.94 Million | 7.09 Million | 1.07 Million |
| Financing Cash Flow | 72.13 Million | -8.05 Million | 3.63 Billion | 7.39 Million | 505.06 Million |
| Debt repayment | -287.35 Million | -14.51 Million | -12.9 Million | -5.61 Million | -5.67 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -32.9 Million | -51.13 Million | -58.15 Million | - | - |
| Common Stock Issuance | - | - | 2.88 Billion | - | - |
| Other Financing Activities | -153.18 Million | 57.59 Million | 834.69 Million | 13.01 Million | 510.73 Million |
| Accounts receivables | -27.09 Million | 3.98 Million | -3.98 Million | - | - |
| Accounts payables | - | -3.98 Million | 3.98 Million | - | - |
| Inventory | -11.85 Million | -28.1 Million | -9.54 Million | -3.54 Million | -3.23 Million |
| Other working capital | 46.8 Million | 22.43 Million | 12.37 Million | 3.35 Million | -3.71 Million |
| Cash at beginning of period | 604.07 Million | 1.52 Billion | 199.4 Million | 432.6 Million | 48.79 Million |
| Cash at end of period | 851.02 Million | 604.07 Million | 1.52 Billion | 199.4 Million | 432.6 Million |
| Capital Expenditure | -382.61 Million | -279.54 Million | -172.85 Million | -19.89 Million | -62.3 Million |
| Effect of forex changes on cash | 10.24 Million | 139.03 Million | -66.65 Million | -8.16 Million | 5.14 Million |
| Net cash flow / Change in cash | 246.95 Million | -916.54 Million | 1.32 Billion | -233.19 Million | 383.8 Million |
| Free Cash Flow | -686.23 Million | -681.48 Million | -387.49 Million | -139.25 Million | -130.68 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -168.37 Million | -168.37 Million | -203.16 Million | -356.18 Million | -203.16 Million | 23.48 Million |
| Depreciation & Amortization | 23.16 Million | 23.16 Million | 21.17 Million | 69.16 Million | 21.08 Million | 13.3 Million |
| Deferred income taxes | - | - | - | - | - | -96.83 Million |
| Stock-based compensation | 8.81 Million | 8.81 Million | 12.19 Million | 40.07 Million | 12.19 Million | 7.84 Million |
| Change in working capital | -29.2 Million | -29.2 Million | 7.71 Million | 22.42 Million | 7.71 Million | -3.79 Million |
| Other non-cash items | -17.36 Million | -17.36 Million | -9.56 Million | -71.51 Million | -9.46 Million | -21.01 Million |
| Investing Cash Flow | -19.93 Million | -19.93 Million | 11.95 Million | 468.2 Million | 11.95 Million | 222.15 Million |
| Investments in PPE | -53.71 Million | -53.71 Million | -38.65 Million | -382.61 Million | -38.65 Million | -124.94 Million |
| Acquisitions | - | - | - | - | - | -170.32 Million |
| Investment purchases | - | - | - | -905.23 Million | - | -705.26 Million |
| Sales/Maturities of investments | - | - | - | 1.6 Billion | - | 1.5 Billion |
| Other Investing Activities | 33.78 Million | 33.78 Million | 50.6 Million | 63.56 Million | 50.6 Million | 347.09 Million |
| Financing Cash Flow | 131.96 Million | 131.96 Million | 38.02 Million | 72.13 Million | 38.02 Million | -1.96 Million |
| Debt repayment | - | - | - | -287.35 Million | - | -218.17 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -16.21 Million | -16.21 Million | -2.07 Million | -32.9 Million | -2.07 Million | -14.37 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 148.17 Million | 148.17 Million | 40.1 Million | -153.18 Million | 40.1 Million | 12.41 Million |
| Accounts receivables | 7.14 Million | 7.14 Million | -9.39 Million | -27.09 Million | -9.39 Million | -4.15 Million |
| Accounts payables | - | - | - | - | - | 21.66 Million |
| Inventory | -13.78 Million | -13.78 Million | 12.03 Million | -11.85 Million | 12.03 Million | -17.96 Million |
| Other working capital | -22.56 Million | -22.56 Million | 5.07 Million | 46.8 Million | 5.07 Million | 18.32 Million |
| Cash at beginning of period | - | - | - | 604.07 Million | - | 678.21 Million |
| Cash at end of period | -70.55 Million | -70.55 Million | -132.08 Million | 851.02 Million | -132.08 Million | 1.2 Billion |
| Capital Expenditure | -53.71 Million | -53.71 Million | -38.65 Million | -382.61 Million | -38.65 Million | -124.94 Million |
| Effect of forex changes on cash | 370 Thousand | 370 Thousand | -10.43 Million | 10.24 Million | -10.43 Million | 15.55 Million |
| Net cash flow / Change in cash | -70.55 Million | -70.55 Million | -132.08 Million | 246.95 Million | -132.08 Million | 524.88 Million |
| Free Cash Flow | -236.67 Million | -236.67 Million | -210.28 Million | -686.23 Million | -210.28 Million | -105.11 Million |
UI
1085
LIGT3
9021
MBT
WTBDY